Home - The YODA Project

Anyone, anywhere in the world should have free, unhindered access to not just my research, but to the research of every great and enquiring mind across the spectrum of human understanding.

Stephen Hawking

Our Mission

The Yale University Open Data Access (YODA) Project’s mission is to advocate for the responsible sharing of clinical research data, open science, and research transparency. The Project is committed to supporting research focused on improving the health of patients and informing science and public health. The YODA Project can only improve with your feedback. Please share your comments and ideas.

Our Model

The YODA Project seeks mutually beneficial partnerships with Data Partners, promoting independence, responsible conduct of research, good stewardship of data, and the generation of knowledge in the best interest of society. To participate, each Data Partner must transfer full jurisdiction over data access to the YODA Project.

How it works

Request Data

Are you ready to request data? To date, 470 trials have been identified as available. The YODA Project and Data Partners continue to identify and add more.

Get started

154 Publications!

Featured Articles

Articles making use of data shared through the YODA Project. Scroll through featured articles below or learn more about approved data requests.

*154 publications from 128 research projects.

View All Featured Articles.

Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations

Rippin G, Sanz H, Hoogendoorn WE, Ballarini NM, Largent JA, Demas E, Postmus D, Framke T, Dávila LMA, Quinten C, Pignatti F. Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations. Drug Saf. 2024 Aug 5. doi: 10.1007/s40264-024-01467-9. Epub ahead of print. PMID: 39102176.
Pooling Alzheimer’s disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action

Dubbelman MA, Vromen EM, Tijms BM, Berkhof J, Ottenhoff L, Vijverberg EGB, Prins ND, van der Flier WM, Sikkes SAM. Pooling Alzheimer’s disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action. Alzheimers Dement (N Y). 2024 Aug 7;10(3):e12485. doi: 10.1002/trc2.12485. PMID: 39114370; PMCID: PMC11303826.
Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications

Kerr WT, Kok N, Reddy AS, McFarlane KN, Stern JM, Pennell PB, Stacey W, French J. Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications. Neurology. 2024 Aug 27;103(4):e209713. doi: 10.1212/WNL.0000000000209713. Epub 2024 Jul 25. PMID: 39052963; PMCID: PMC11271390.
Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data

Hanlon P, Butterly E, Shah ASV, Hannigan LJ, Wild SH, Guthrie B, Mair FS, Dias S, Welton NJ, McAllister DA. Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data. BMC Med. 2022 Oct 28;20(1):410. doi: 10.1186/s12916-022-02594-9. PMID: 36303169; PMCID: PMC9615407.
Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn’s Disease: A Post Hoc Analysis of the REACH Trial

Cheifetz AS, Vande Casteele N, Wang Z, Dubinsky MC, Papamichael K. Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn’s Disease: A Post Hoc Analysis of the REACH Trial. Am J Gastroenterol. 2023 Mar 1;118(3):485-490. doi: 10.14309/ajg.0000000000002096. Epub 2022 Dec 23. PMID: 36624036; PMCID: PMC9991960.
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

Bayani DB, Lin YC, Nagarajan C, Ooi MG, Tso ACY, Cairns J, Wee HL. Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers. Pharmacoecon Open. 2024 Sep;8(5):651-664. doi: 10.1007/s41669-024-00503-9. Epub 2024 Jun 20. PMID: 38900407; PMCID: PMC11362436.
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials

Vuyyuru SK, Ma C, Nguyen TM, Zou G, Peyrin-Biroulet L, Danese S, Dulai P, Narula N, Singh S, Jairath V. Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials. EClinicalMedicine. 2024 May 4;72:102621. doi: 10.1016/j.eclinm.2024.102621. PMID: 38726222; PMCID: PMC11079462.
Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials

Wang D, Ling Y, Harris K, Schulz PE, Jiang X, Kim Y. Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials. medRxiv [Preprint]. 2023 Oct 30:2023.10.27.23297685. doi: 10.1101/2023.10.27.23297685. PMID: 37961216; PMCID: PMC10635230.
Personalizing treatment selection in Crohn’s disease: a meta-analysis of individual participant data from fifteen randomized controlled trials

Rudrapatna VA, Ravindranath VG, Arneson DV, Mosenia A, Butte AJ, Wang S. Personalizing treatment selection in Crohn’s disease: a meta-analysis of individual participant data from fifteen randomized controlled trials. medRxiv [Preprint]. 2023 Nov 12:2023.11.10.23291837. doi: 10.1101/2023.11.10.23291837. PMID: 37986977; PMCID: PMC10659518.
Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity

Guo X, Bourgeois FT, Cai T. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity. Stat Methods Med Res. 2024 Jul;33(7):1152-1162. doi: 10.1177/09622802241247719. Epub 2024 May 8. PMID: 38717356.